Why this result mattered
Functional tie
The principal comparison placed Qwen 3.8 and Claude under concealed A/B labels.
Both answers place LumaBio on the same material path: preserve evidence, issue a specific deduction notice, verify performance under compliant humidity and film conditions, avoid immediate litigation or continued unsecured withholding, and negotiate an engineering remedy plus a supported credit. Both conclude that rejection and revocation are unavailable, consequential damages are contractually excluded absent fraud, fraud is impaired by reliance evidence, and an adverse inference is unlikely without intent.
Fast audit
Open the underlying record
These links open all four answers, the principal blind judgment, original prompt, and sealed key.
Prompt and sealed key
The key is an audit reference. It was not shown to the contestant systems and did not determine the comparative verdict.
Read the original matter prompt
Question 1: The Pharmaceutical Packaging Line
Your role
You represent LumaBio, a pharmaceutical manufacturer, after a dispute with PrecisionFill over a packaging line. LumaBio must decide whether to pay the final contract installment, pursue litigation, or negotiate a commercial resolution.
Governing law
Assume the following Commercial Code rules apply:
A factual affirmation, description, promise, model, or sample that becomes part of the basis of the bargain creates an express warranty. Formal words such as “warranty” are unnecessary. General praise and sales opinion do not create a warranty.
A completely integrated written agreement excludes prior or contemporaneous agreements that contradict it. Consistent explanatory evidence may still be used if the writing is only partially integrated. Course of performance may explain ambiguous terms and may support waiver.
A merger clause and a clause stating that a party did not rely on prior representations are relevant to reasonable reliance. They do not automatically defeat a fraud claim based on an intentionally false factual representation concerning information peculiarly within the speaker’s knowledge.
A buyer accepts goods when, after a reasonable opportunity to inspect, it signifies acceptance or fails to make an effective rejection. A buyer may revoke acceptance only if a nonconformity substantially impairs the goods’ value and the original acceptance was reasonably induced by difficulty discovering the defect or by the seller’s assurances. Revocation must occur within a reasonable time and before a substantial change not caused by the defect.
Continued use after attempted revocation may undermine revocation, although limited use necessary to avoid serious loss does not automatically defeat it.
The buyer must notify the seller of breach within a reasonable time after discovering or when it should have discovered the breach. Actual seller knowledge may affect whether formal notice was sufficient.
An exclusive repair or replacement remedy fails of its essential purpose if the seller cannot or will not provide an effective cure within a reasonable time. A separate exclusion of consequential damages remains enforceable unless unconscionable or expressly made dependent on the exclusive remedy. Consequential-damage exclusions between sophisticated commercial parties are ordinarily enforceable.
Direct damages may include the difference between the value promised and the value delivered. Incidental and consequential damages require foreseeability, causation, reasonable certainty, and mitigation.
A buyer may deduct damages from an unpaid price after notifying the seller of its intention to do so.
Fraud requires a material false statement of present or past fact, knowledge or reckless disregard of falsity, intent to induce reliance, reasonable reliance, and resulting loss. A promise about future performance is actionable only if the speaker had no present intention to perform or misrepresented an existing technical capability.
A party must preserve relevant evidence when litigation is reasonably anticipated. Negligent loss may justify measures curing proven prejudice. An adverse inference requires intent to deprive the opposing party of the evidence.
Contract
LumaBio agreed to pay $4.8 million for a sterile vial-packaging line. The contract contains the following provisions:
- “Rated throughput: 300 vials per minute.”
- Site acceptance requires a four-hour test averaging at least 285 vials per minute, with no more than 3 percent rejected units.
- The test must occur at 35 to 45 percent relative humidity.
- The test must use LumaBio’s packaging film, provided that the film meets the variance specifications in Schedule B.
- PrecisionFill warrants for twelve months that the line will conform to the written specifications and be free from defects in materials and workmanship.
- Repair or replacement is the exclusive remedy.
- PrecisionFill disclaims implied warranties of merchantability and fitness.
- PrecisionFill’s total liability is capped at the purchase price.
- PrecisionFill is not liable for lost profits, lost production, customer penalties, or other consequential damages.
- The liability limitations do not apply to fraud, gross negligence, or willful misconduct.
- The consequential-damage exclusion remains effective even if the exclusive remedy fails of its essential purpose.
- The writing is the complete agreement, and LumaBio states that it did not rely on statements not contained in the contract.
Before signing, PrecisionFill’s vice president emailed LumaBio’s project leader:
“This line will run 300 all day in your facility on your current film. If it cannot, we will take it back and make you whole.”
LumaBio’s project leader forwarded the email internally and wrote:
“Their contract only guarantees a 285 acceptance test. We should add the 300 commitment, but procurement wants this signed today.”
No change was made.
Facts
At PrecisionFill’s factory, the line averaged 302 vials per minute using PrecisionFill’s film. At LumaBio’s facility, it averaged 287 vials per minute with a 2.6 percent rejection rate during a four-hour test at 42 percent humidity. LumaBio signed a certificate stating:
“Site acceptance completed, subject to punch-list items and sustained production validation.”
The certificate did not identify the sustained-production criteria.
During the next three weeks, the facility humidity ranged from 52 to 60 percent because LumaBio’s HVAC project was incomplete. The line averaged between 238 and 260 vials per minute and repeatedly jammed. PrecisionFill’s technician blamed the humidity.
After the HVAC system was repaired, the line operated at 39 to 43 percent humidity but averaged only 270 vials per minute. PrecisionFill then discovered a feed-control software problem. It delivered a patch six weeks later. After the patch, the line averaged 286 to 289 vials per minute during ordinary production. It occasionally reached 300 for periods of several minutes.
Approximately 18 percent of LumaBio’s film lots exceeded Schedule B’s permitted thickness variance. LumaBio possessed pre-contract quality-control data showing that some lots exceeded the limits, but no one gave that data to PrecisionFill. The line performed worse when those lots were used, although it still rarely exceeded 290 with compliant lots.
A PrecisionFill engineer wrote in an internal chat before signing:
“Sales keeps telling them 300. With their film, this architecture probably tops out around 288 unless we redesign the feeder.”
Another engineer responded:
“Three hundred is technically possible with perfect film and enough tuning. Do not put 288 in writing.”
LumaBio incurred overtime, temporary labor, and expedited-shipping expenses. It also lost a major customer order. PrecisionFill knew before contracting that LumaBio intended to use the line for that customer, but the contract expressly excludes lost-customer and lost-profit damages.
LumaBio first sent a formal breach notice 75 days after sustained production began. PrecisionFill’s technicians had been working on the performance problem since the first week. LumaBio continued using the line for eight months and withheld the final $900,000 installment.
PrecisionFill’s system automatically overwrote raw diagnostic telemetry after 30 days. LumaBio sent an email on day 25 stating that it was “considering all contractual and legal remedies.” The raw telemetry was overwritten on day 30. PrecisionFill preserved summary reports but did not suspend the automatic deletion.
Assignment
Analyze:
- Whether PrecisionFill breached an express warranty or another contractual obligation.
- Whether the pre-contract email is admissible or independently actionable as fraud.
- The significance of the 285-vial acceptance standard, the 300-vial rated-throughput term, the acceptance certificate, and the parties’ subsequent conduct.
- Whether LumaBio could reject or revoke acceptance.
- Whether notice was timely.
- Whether the repair remedy failed of its essential purpose.
- Which claimed damages are recoverable.
- Whether LumaBio properly withheld the final installment.
- Whether the deleted telemetry supports sanctions or an adverse inference.
- The strongest defenses based on humidity, film variance, contract language, reliance, causation, and mitigation.
- Whether LumaBio should litigate, pay the withheld amount, demand additional engineering work, or negotiate a commercial settlement.
Read the sealed key
Q1 key (Packaging Line)
- The 285-vials acceptance test is the operative contract floor; the 300 "rated throughput" line and pre-signing email support warranty and fraud theories but do not convert 300 into the pass/fail standard. Missed: client sets demands around an unwinnable 300 baseline.
- The fraud theory is viable despite the merger and no-reliance clauses because the internal engineer messages evidence a knowing present-capability misrepresentation, and the contract's own carve-out removes the caps for fraud. Missed: client forfeits its only path around the damages exclusions.
- Revocation of acceptance is weak: signed certificate, eight months of continued use, and 18 percent noncompliant film. Advise against staking the case on revocation. Missed: client pursues a losing rescission posture.
- Notice is defensible: seller worked the problem from week one; actual knowledge substitutes under supplied rule 6. Missed: client concedes a curable defense.
- Consequential damages, including the lost customer, are excluded even if the repair remedy failed, because the contract expressly preserves the exclusion; only the fraud route reaches them. Missed: exposure and leverage misvalued by seven figures.
- Withholding the $900,000 is defensible only with notice of deduction; advise sending or confirming that notice now. Missed: client converts leverage into its own breach.
- Telemetry loss: duty plausibly arose at the day-25 email; negligent loss supports curative measures at most, not an adverse inference. Missed: sanctions expectations misset.
- Posture: negotiate a commercial resolution (engineering fix plus price adjustment), using the fraud carve-out as leverage; do not litigate first. Missed: value destroyed relative to the achievable deal.
Direct judge report
The report below is preserved from the Qwen 3.8 versus Claude verdict record.
Read the preserved judge report
Basis. Both answers place LumaBio on the same material path: preserve evidence, issue a specific deduction notice, verify performance under compliant humidity and film conditions, avoid immediate litigation or continued unsecured withholding, and negotiate an engineering remedy plus a supported credit. Both conclude that rejection and revocation are unavailable, consequential damages are contractually excluded absent fraud, fraud is impaired by reliance evidence, and an adverse inference is unlikely without intent.
[A] rejected: $250,000–$700,000 recovery range, $300,000–$400,000 retention, and proposed settlement figures — record lacks engineering costs, valuation evidence, expense amounts, and lost-order value.
[A] rejected: likely reciprocal fraud or negligent-misrepresentation counterclaim — record lacks a stated disclosure duty or governing negligent-misrepresentation rule.
[A] rejected: over-withholding necessarily creates fee and interest exposure — record lacks fee and interest provisions.
Failed candidates.
Treatment of operating expenses as partly incidental versus mostly consequential — different conduct failed; both require documentation, causation analysis, apportionment, and negotiation.
Continuing obligation to sustain at least 285 vials per minute — different conduct failed; both call for controlled testing and a defined sustained-performance protocol.
Strength and characterization of the fraud claim — different conduct failed; both preserve it as settlement leverage while treating reliance as a major obstacle.
Revocation-inducement rationale — different conduct failed; both conclude that revocation is unavailable.
Interpretive use of the pre-contract email — exact difference failed; both permit its possible use to explain an ambiguous written term while rejecting it as an independent contract term.
Telemetry remedies — concrete consequence failed; neither establishes prejudice supporting a particular curative measure, and both reject an adverse inference on the present record.
Payment mechanics — different conduct failed after neutralization; both advise replacing naked withholding with notice, supported valuation, and escrow or calibrated payment.
Willful-misconduct characterization — different conduct failed; both rely primarily on fraud and recommend negotiation rather than immediate suit.
Hard stop. The sentence cannot be completed with a concrete, record-supported consequence because both answers lead LumaBio to the same materially safe legal and commercial course.
All six pairings
Every pair of the four model answers was judged independently under the same evaluation instrument.
Open the six head-to-head results
| Pairing | Result | Why it mattered | Record |
|---|---|---|---|
| Qwen 3.8 27B vs Claude Opus 5 | Functional tie | Both answers place LumaBio on the same material path: preserve evidence, issue a specific deduction notice, verify performance under compliant humidity and film conditions, avoid immediate litigation or continued unsecured withholding, and negotiate an engineering remedy plus a supported credit. | Judge record |
| Qwen 3.8 27B vs DeepSeek V4-Flash-0731 | Functional tie | Both answers put LumaBio on the same material path: treat rejection and revocation as unavailable, preserve and specify its warranty/fraud claims, give explicit setoff notice, protect the disputed installment through escrow or negotiation, demand engineering relief, and litigate only if settlement fails. | Judge record |
| Qwen 3.8 27B vs Qwen 3.5 27B | Functional tie | Both answers place LumaBio on the same material path: treat rejection or revocation as weak, preserve and formally notice its breach and setoff positions, pursue engineering work and a negotiated credit, and reserve litigation principally as fraud leverage. | Judge record |
| DeepSeek V4-Flash-0731 vs Claude Opus 5 | Functional tie | Both answers place LumaBio on the same material path: give explicit deduction notice, avoid immediate litigation or unconditional payment, seek an engineered cure and commercial settlement, and preserve warranty and fraud claims while recognizing that revocation and consequential damages are unlikely absent… | Judge record |
| DeepSeek V4-Flash-0731 vs Qwen 3.5 27B | Functional tie | Both answers lead LumaBio to negotiate before litigating, maintain the withholding only with explicit offset notice, demand an engineering cure, preserve breach and fraud claims, and treat rejection or revocation as impractical. | Judge record |
| Qwen 3.5 27B vs Claude Opus 5 | Functional tie | Both answers place LumaBio on the same material path: treat the line as accepted, preserve warranty and fraud theories, recognize that consequential damages remain excluded absent fraud, provide a specific deduction notice, and negotiate an engineering cure plus price credit rather than immediately… | Judge record |
Rejected-point diagnostic
Judge-attributed rejected points for this matter across all six pairings:
| Qwen 3.8 27B | 0 |
|---|---|
| DeepSeek V4-Flash-0731 | 3 |
| Claude Opus 5 | 8 |
| Qwen 3.5 27B | 7 |
This is a review-burden diagnostic, not a universal hallucination measure.